AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04016701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floreo Joint Attention Module
Description: Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
Study NCT04016701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regularly Scheduled Therapy
Description: therapy as regularly scheduled at therapy center
Study NCT04616937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GOS
Description: Prebiotic
Study NCT04616937 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00771173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered q8 hours for 24 hours postop.
Study NCT00700895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
Study NCT01462448 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Single blood draw of 30 ml
Study NCT01586806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Only
Description: This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
Study NCT01586806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 1 mg of Dexamethasone
Description: This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
Study NCT01586806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 4 mg of Dexamethasone
Description: This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
Study NCT03409029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Additional imaging using MRI scan
Study NCT00992186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carlumab
Description: Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
Study NCT01718470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Description: Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
Study NCT00166270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study NCT04156620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
Study NCT04156620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
Study NCT01957566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APS
Study NCT02724865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnodent® (Oral appliance therapy)
Study NCT02724865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst® (Oral appliance therapy)
Study NCT01829217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT01841528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fresh embryo transfer
Description: rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
Study NCT01841528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frozen-thawed embryo transfer
Description: rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
Study NCT01153477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling - Enhanced
Description: Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
Study NCT00003077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Study NCT04611178 — intervention group
Intervention type: DEVICE
Intervention: Mechanical thrombectomy
Description: Stent retriever for treatment of cerebral arterial occlusions
Study NCT04354155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
Study NCT02147821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Pleural Chest Tube
Study NCT02878083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEDOLIZUMAB
Description: Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
Study NCT02878083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADALIMUMAB
Description: For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
Study NCT03601390 — intervention group
Intervention type: DEVICE
Intervention: PET/CT and EBV DNA
Description: PET/CT and EBV DNA will be proformed after the IMRT treatment
Study NCT02727322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
Study NCT02727322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00614133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with glucose and amino acids
Description: Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
Study NCT00614133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nutrition with glucose and amino acids.
Description: Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
Study NCT02898922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
Description: 20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
Study NCT02898922 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
Description: 20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
Study NCT00772278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid artery stenting
Description: carotid artery angiography, angioplasty and stenting
Study NCT00772278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: open surgery including endarterectomy
Study NCT01936233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 0.1 QD po
Study NCT01936233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: LAminvudine 0.1 QD po
Study NCT01936233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: LAminvudine 0.1 QD po
Study NCT01336348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg loading dose given orally at presentation
Study NCT01336348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
Study NCT02246491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A-T iPS cell line
Description: Reprogramming A-T patients iPS cell line
Study NCT02246491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carrier patients iPS cell line
Description: Reprogramming iPS cell line from carrier patients
Study NCT05124717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)
Description: One tablet of the Test product was administered orally with 240 mL of water.
Study NCT05124717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Description: One tablet of the Reference product was administered orallyn with 240 mL of water.
Study NCT04749745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-theanine
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
Study NCT04749745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-theanine
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
Study NCT04749745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
Study NCT04749745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
Study NCT04313738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Home visit, health education
Study NCT02061475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Patches
Study NCT03225482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced Compensatory Cognitive Training
Description: ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
Study NCT03225482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-focused Supportive Contact
Description: SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
Study NCT03007771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided High-Intensity Focused Ultrasound
Description: -Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
Study NCT02125955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: Dissolved in water.
Study NCT02125955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dissolved in water
Study NCT02136914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Description: Oral capsules to be administered once nightly at bedtime, for 25 weeks
Study NCT02136914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules to be administered once nightly at bedtime, for 25 weeks
Study NCT02312648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional Group
Description: Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
Study NCT02312648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
Study NCT01720394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Ripening Balloon, Cook Medical Inc.
Description: Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
Study NCT01720394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
Study NCT01493089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: 20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
Study NCT01493089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losec
Description: 20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
Study NCT00830050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 500 mg BID 7 days
Study NCT00830050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID 7 days
Study NCT04076332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
Study NCT03488329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Individual nutritional therapy
Description: Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition.
Study NCT01870869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
Description: Surgical implant
Study NCT01569412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ertumaxomab
Description: trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
Study NCT03221478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping placebo and exercises
Description: Kinesio Taping placebo and exercises
Study NCT03221478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension and exercises
Description: Kinesio Taping with tension and exercises
Study NCT03221478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping with tension
Description: Kinesio Taping with tension
Study NCT01566357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Study NCT01566357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk
Study NCT01566357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated Milk
Study NCT01566357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Mousse
Study NCT01566357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MI Paste Plus
Study NCT01566357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elmex Erosion Protection
Study NCT02991430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active neuromodulation for episodic migraine headache
Description: Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
Study NCT02991430 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo neuromodulation for episodic migraine headache
Description: Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
Study NCT01434862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Closed loop with pramlintide
Description: Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
Study NCT01434862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop without pramlintide
Description: This visit will assess how well the closed loop system works without the pramlintide.
Study NCT01434862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open loop with pramlintide
Description: Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.